Navigation Links
Study compares effectiveness of 2 vs. 3 doses of HPV vaccine for girls and young women
Date:4/30/2013

With the number of doses and cost of human papillomavirus (HPV) vaccines a barrier to global implementation, researchers have found that girls who received two doses of HPV vaccine had immune responses to HPV-16 and HPV-18 infection that were noninferior to (not worse than) the responses for young women who received three doses, according to a study in the May 1 issue of JAMA, a theme issue on child health. The authors note that more data on the duration of protection are needed before reduced-dose schedules can be recommended.

Simon R. M. Dobson, M.D., of the University of British Columbia, Vancouver, presented the findings of the study at a JAMA media briefing.

"Globally, cervical cancer is the second most common cause of cancer morbidity and mortality in women. Human papillomavirus infection has been identified as a necessary cause for the development of cervical cancer, with HPV genotypes 16 and 18 accounting for approximately 70 percent of cervical cancer cases," according to background information in the article. "Global use of HPV vaccines to prevent cervical cancer is impeded by cost. A 2-dose schedule for girls may be possible."

Dr. Dobson and colleagues conducted a study to determine whether average antibody levels to HPV-16 and HPV-18 among girls receiving 2 doses were noninferior to women receiving 3 doses. The authors also looked at antibody levels to HPV-6 and HPV-11, and compared girls given 2 or 3 doses. The randomized, phase 3, multicenter study included 830 Canadian females from August 2007 through February 2011. Follow-up blood samples were provided by 675 participants (81 percent). Girls (9-13 years of age) were randomized 1:1 to receive 3 doses of quadrivalent HPV vaccine at 0, 2, and 6 months (n=261) or 2 doses at 0 and 6 months (n=259). Young women (16-26 years of age) received 3 doses at 0, 2, and 6 months (n=310). Antibody levels were measured at 0, 7, 18, 24, and 36 months.

The researchers found that the geometric mean titer (GMT) antibody levels in girls receiving 2 doses were noninferior to the respective GMTs in women receiving 3 doses for all 4 genotypes, with GMT ratios of 2.07 for HPV-16 and 1.76 for HPV-18. "Girls given 2 doses vs. 3 doses had a noninferior antibody response for all 4 vaccine genotypes," with GMT ratios of 0.95 for HPV-16 and 0.68 for HPV-18.

"The GMT ratios for girls (2 doses) to women (3 doses) remained noninferior for all genotypes to 36 months. Antibody responses in girls were noninferior after 2 doses vs. 3 doses for all 4 vaccine genotypes at month 7, but not for HPV-18 by month 24 or HPV-6 by month 36."

The authors write that these are the first data, to their knowledge, "on the duration of the immune response of young adolescent girls to a reduced-dose schedule of quadrivalent HPV vaccine out to 3 years." However, "The clinically meaningful difference between the 2- and 3-dose schedules cannot yet be determined."

"Reducing the number of doses affects vaccine and administration costs as well as potentially improving uptake rates. Evidence-based decision making in public health has led to reduced-dose schedules for hepatitis B, pneumococcal, and meningococcal serogroup C vaccine programs. There is a balance to be found between the incremental value of an additional dose on population effectiveness and the opportunity costs of using the resources required for the extra dose in other public health programs. This is especially the case for HPV vaccines at their present cost."

(JAMA. 2013;309(17):1793-1802; Available pre-embargo to the media at http://media.jamanetwork.com)

Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

There will also be a digital news release available for this study, including the JAMA Report video, embedded and downloadable video, audio files, text, documents, and related links. This content will be available at 3 p.m. CT Tuesday, April 30 at this link.

Editorial: HPV Vaccination - Too Soon for 2 Doses?

" the study by Dobson et al provides encouraging preliminary evidence that a 2-dose quadrivalent HPV vaccine series in girls may be as immunogenic as a 3-dose series in women, although the duration of protection may be less," writes Jessica A. Kahn, M.D., M.P.H., and David I. Bernstein, M.D., M.A., of the Cincinnati Children's Hospital Medical Center and the University of Cincinnati College of Medicine, in an accompanying editorial.

"If future studies establish that a 2-dose series leads to a durable immune response and effectively prevents HPV-related cancers in both women and men, the benefits would be substantial for reducing the global burden of cervical cancer and other HPV-related diseases. The potential to further reduce morbidity and mortality due to HPV-related cancers would be especially significant in less developed regions of the world, where the cost of vaccination and implementation of adolescent vaccination programs present significant barriers, but where primary prevention strategies are most urgently needed."

(JAMA. 2013;309(17):1832-1833; Available pre-embargo to the media at http://media.jamanetwork.com)

Editor's Note: Please see the article for additional information, including financial disclosures, funding and support, etc.


'/>"/>

Contact: Brian Lin
brian.lin@ubc.ca
604-822-2234
The JAMA Network Journals
Source:Eurekalert

Related medicine news :

1. New Medical Study Finds Reed Migraine Centers’ Migraine Treatment Highly Effective in Controlling Severe Pain in Majority of Patients
2. Your Voice Carries Sexual Cues, Study Finds
3. Water Pipe No Safer Than Cigarettes: Study
4. Penn pilot study: Group of Bradford Co, Pa. residents concerned about health effects of hydrofracking
5. Great HealthWorks, Inc., makers of Omega XL, Report New Independent Study: Omega-3 DHA Protects Against Liver Disease
6. Mirena Lawsuits: Bernstein Liebhard LLP Disturbed by New Study Finding IUDs Safe for Teens, In Light of Alleged Mirena Complications
7. Interns Schedules Shortchange Patients, Study Suggests
8. Doctors Feel Less Connected to Obese Patients, Study Suggests
9. Forthcoming study explores use of intermittent fasting in diabetes as cardiovascular disease
10. Contract Research Organization WCCT Global Announces Overwhelming Success of Pediatric Clinical Study Recruitment
11. More Infants Surviving With Serious Heart Defects, Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... From March 4 through 6, ... Annual Meeting at the Walter E. Washington Convention Center in Washington, D.C. , ... condition of hyperhidrosis (excessive sweating) and its treatment options. Specifically, the company will ...
(Date:2/11/2016)... ... February 11, 2016 , ... Husted Kicking has completed its ... on February 6th & 7th, 2016 according to kicking coach Michael Husted. , “This ... to the NFL’s combine in Indianapolis,” says Husted. “The NFL uses a third party ...
(Date:2/11/2016)... , ... February 11, 2016 , ... The book, “Computers ... IT services, what questions to ask your IT consultant before signing a contract and ... your computer network. , “With companies relying heavily on e-mail and technology, it’s more ...
(Date:2/11/2016)... AZ (PRWEB) , ... February 11, 2016 , ... As ... with support of the Million Dollar Round Table Foundation (MDRTF), has gifted $10,000 to ... according to Colleen’s Dream Foundation President Billy Cundiff. , “We are honored to support ...
(Date:2/10/2016)... ... February 10, 2016 , ... The 9th annual meeting ... Congress (WMIC), will be held in New York City, NY on September 7 ... The congress will highlight and emphasize how imaging reveals a greater understanding of ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... The primary goal of this research is ... the usage of liquid biopsy. Key information the survey ... Timeframe of liquid biopsy adoption amidst future users - ... type - Sample inflow to conduct liquid biopsy tests ... and so on. - Correlation analysis of sample type ...
(Date:2/11/2016)... Calif., Feb. 11, 2016 PRO-DEX, INC. (NasdaqCM: PDEX) ... ended December 31, 2015. The Company also filed its Quarterly ... year 2016 with the Securities and Exchange Commission today. ... 31, 2015 --> --> ... increased $2.6 million, or 95%, to $5.4 million from $2.8 ...
(Date:2/11/2016)...  Kindred Biosciences, Inc. (NASDAQ: KIN ), a ... of pets, today announced the submission to FDA of ... Application (NADA) for Zimeta™ (dipyrone injection, KIND-012).  Positive topline ... for the control of pyrexia (fever) in horses were ... --> The Chemistry, Manufacturing, and Controls ...
Breaking Medicine Technology: